valemetostat tosylate
valemetostat tosylate is a pharmaceutical drug with 7 clinical trials. Currently 6 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
1 of 1 finished
0.0%
0 ended early
6
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
Clinical Trials (7)
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma
Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7